NCT07244211 MAPT Protocol: Fixation Versus Arthroplasty Surgical Treatments for Early Recovery After HIP Fracture (FASTER-HIP)
| NCT ID | NCT07244211 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Southern California |
| Condition | Femoral Neck Fractures |
| Study Type | INTERVENTIONAL |
| Enrollment | 600 participants |
| Start Date | 2026-01-23 |
| Primary Completion | 2029-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 600 participants in total. It began in 2026-01-23 with a primary completion date of 2029-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is an intervention domain of the Musculoskeletal Adaptive Platform Trial. The primary goal of this pragmatic, randomized, open-label, comparative effectiveness trial is to evaluate if arthroplasty is superior to internal fixation when used to treat minimally displaced femoral neck fractures in older adults ≥60 years old. We hypothesize that arthroplasty will reduce death, preserve ambulation, increase days alive and out of hospital, and improve health status compared to internal fixation within 4 months and 12 months from randomization.
Eligibility Criteria
Inclusion Criteria: * 60 years of age or older undergoing surgery due to a minimally displaced femoral neck fracture * The patient has a health condition affecting physical mobility. * Complete fracture of the femoral neck (AO/OTA 31B) confirmed with anteroposterior and lateral hip radiographs, computed tomography, or magnetic resonance imaging. * Minimally displaced fracture that could be, in the judgment of the attending surgeon, managed with either arthroplasty or in situ internal fixation without reduction. * Low energy injury mechanism. * Surgeons with expertise in internal fixation and total hip arthroplasty or hemiarthroplasty are available to perform surgery. Exclusion Criteria: * The patient is not clinically suitable for either compared treatment. * Expected injury survival of less than 12 months. * Terminal illness with expected survival of less than 12 months. * Incarceration. * Unable to obtain informed consent due to language barriers. * Unable to obtain informed consent because the legally authorized representative was unavailable. * Problems, in the judgment of the study personnel, with maintaining follow-up with the patient. * Currently enrolled in a study or intervention domain that does not permit co-enrollment. * Prior enrollment in the specific platform trial intervention domain. * Patient or legally authorized representative did not provide informed consent (declined participation). * Eligible patient or legally authorized representative was not approached within the screening window (missed participant). * Other reasons to exclude the patient, as approved by the data coordinating center. * Associated lower extremity injury that prevents post-operative weight-bearing. * Retained hardware around the hip that precludes either study treatment. * Infection around the hip (soft tissue or bone). * Pathologic fracture with a lytic lesion in the femoral neck that precludes internal fixation. * Injury did not occur within 21 days of screening. * Patient is too ill, in the judgment of the attending surgeon, for internal fixation. * Patient is too ill, in the judgment of the attending surgeon, for arthroplasty.
Contact & Investigator
Joseph T Patterson, MD
PRINCIPAL INVESTIGATOR
University of Southern California
Frequently Asked Questions
Who can join the NCT07244211 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, studying Femoral Neck Fractures. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07244211 currently recruiting?
Yes, NCT07244211 is actively recruiting participants. Contact the research team at OrthoTraumaResearch@med.usc.edu for enrollment information.
Where is the NCT07244211 trial being conducted?
This trial is being conducted at Irvine, United States, Los Angeles, United States, Los Angeles, United States, Los Angeles, United States and 11 additional locations.
Who is sponsoring the NCT07244211 clinical trial?
NCT07244211 is sponsored by University of Southern California. The principal investigator is Joseph T Patterson, MD at University of Southern California. The trial plans to enroll 600 participants.